Gene · 970
NIH grants2,135
NIH grants whose papers are about the gene, through NIH's grant-paper links.
681 to 700 of 2,135
Download this page as JSON| Grant | Title | CD70 papers | Newest fiscal year |
|---|---|---|---|
| R00HG009917 | Systematic mapping and prediction of gene-enhancer connections | 1 | 2022 |
| R01AG050582 | The Role of Somatic Transposition in Age-associated Genomic Instability | 1 | 2022 |
| R01AI132798 | Innate modulation of autoimmune, regulatory, and effector B cells in adipose tissue | 1 | 2022 |
| R01AI134861 | Immunometabolic and epigenetic effects of obesity on innate immune surveillance in cancer | 1 | 2022 |
| R01AI137337 | Metabolic Network Remodeling in Epstein-Barr Virus Lymphomagenesis | 1 | 2022 |
| R01AI139633 | Mechanisms of a Novel Combined Immunodeficiency Caused by a Homozygous Mutation in COPG1 | 1 | 2022 |
| R01AI141609 | lncRNA Control of Airway Epithelial Cell Responses to Type 2 Inflammation | 1 | 2022 |
| R01AR070148 | Characterizing the Takayasu arteritis genetic risk in RPS9/LILRB3 | 1 | 2022 |
| R01AR071944 | Elucidating the Cellular and Molecular Mechanisms of How Regulatory T cells in Skin Regulate Fibroblast Activation and Tissue Fibrosis | 1 | 2022 |
| R01CA151354 | Biological Validation of Candidate Myeloma Driver Genes | 1 | 2022 |
| R01CA155169 | Understanding Resistance to Next Generation Antiandrogens | 1 | 2022 |
| R01CA172896 | Understanding the niche of minimal residual disease leukemia cells | 1 | 2022 |
| R01CA174844 | A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia | 1 | 2022 |
| R01CA205633 | Inhibition of Oral Tumorigenesis by Antitumor B | 1 | 2022 |
| R01CA216855 | A novel microfluidic device to predict brain cancer prognosis and response to therapy | 1 | 2022 |
| R01CA222965 | Glioma immunotherapy targeting IDH mutation-derived epitope and immunosuppression | 1 | 2022 |
| R01CA223150 | In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices | 1 | 2022 |
| R01CA223804 | Transfer Application - R01 CA223804 - Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer | 1 | 2022 |
| R01CA226851 | Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy | 1 | 2022 |
| R01CA226983 | Directing the metabolic fate of CAR T cells | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/grants?page=35